Recent clinical trials and optical control as a potential strategy to develop microtubule-targeting drugs in colorectal cancer management

doi:10.3748/wjg.v30.i13.1780

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 13

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2726)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

HTML

1746

Figures (1-3)

220

Tables (1-3)

274

Sum=2309

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

222

Sum=301

Apr 7, 2024 (publication date) through Dec 22, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Apr 7, 2024; 30(13): 1780-1790
Published online Apr 7, 2024. doi: 10.3748/wjg.v30.i13.1780

Recent clinical trials and optical control as a potential strategy to develop microtubule-targeting drugs in colorectal cancer management

Katsuhiro Kita, Allen Burdowski

Katsuhiro Kita, Allen Burdowski, Department of Biology, St. Francis College, Brooklyn, NY 11201, United States

Author contributions: Kita K and Burdowski A conceived the idea and wrote the manuscript.

Conflict-of-interest statement: The author declares no conflict of interests.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Katsuhiro Kita, PhD, Assistant Professor, Department of Biology, St. Francis College, 179 Livingston Street, Brooklyn, NY 11201, United States. kkita@sfc.edu

Received: December 27, 2023
Peer-review started: December 27, 2023
First decision: January 10, 2024
Revised: February 8, 2024
Accepted: March 19, 2024
Article in press: March 19, 2024
Published online: April 7, 2024
Processing time: 97 Days and 10.6 Hours

Core Tip

Core Tip: This review article proposes a potentially new approach to utilize photo-switchable microtubule (MT)-targeting drugs in colorectal cancer (CRC). First, we will start the introduction of CRC and current therapy as well as some updates in 2023. Then, we list a popular MT-targeting drug family, taxanes in CRC. As many readers may be aware, taxanes are not really effective in CRC for some reason. Here, we would like to shed light on optically controllable MT-targeting drugs as potential new drug candidates in CRC management.